Opus Genetics, Inc. Recapitalization Costs
Opus Genetics, Inc. (IRD) reported Recapitalization Costs of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RecapitalizationCosts · last filed 2022-03-24
- Opus Genetics, Inc. recapitalization costs for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Opus Genetics, Inc. recapitalization costs for fiscal 2020 was $689.00K.
- Opus Genetics, Inc. recapitalization costs for fiscal 2019 was $0.00.
| Period end | Recapitalization Costs 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-24 |
| 2020-12-31 | $689.00K 10-K · filed 2022-03-24 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |